RxDoctor Payments Data

John Pope, MD

Family Medicine · Shreveport, LANPI 1588682058

Payments from drug & device makers

$5,576in general payments, 2019–2025

Across 382 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$876
  • Novo Nordisk$772
  • Boehringer Ingelheim$507
  • Merck$406
  • Lilly USA, LLC$376
  • AstraZeneca$350
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,551100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,576 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$207,855
Medicare patients
301
Services billed
8,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$46,342
JardianceEmpagliflozin28$22,169
Nurtec OdtRimegepant Sulfate11$20,500
JanuviaSitagliptin Phosphate15$18,610
OzempicSemaglutide14$13,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,213
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$10,796
MyrbetriqMirabegron11$9,277
EliquisApixaban15$8,287
Colesevelam Hcl11$4,642
Atorvastatin Calcium255$3,644
Dexlansoprazole DrDexlansoprazole12$1,946
Omeprazole95$1,725
Metoprolol Succinate62$1,188
Tamsulosin Hcl79$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$376$46,34248 claims
PfizerNurtec Odt, Eliquis$244$28,78726 claims
Boehringer IngelheimJardiance$507$22,16928 claims
MerckJanuvia$406$18,61015 claims
Novo NordiskOzempic$772$13,07014 claims
GSKTrelegy Ellipta$217$11,21312 claims
Astellas Pharma US IncMyrbetriq$139$9,27711 claims
AbbVieSynthroid$876$1,07626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →